Brought to you by 
Pharmion licenses cancer candidate from MethylGene
22 Jun 2021
Executive Summary
Pharmion (oncology and hematology therapeutics) has licensed from fellow cancer drug developer MethylGene research, development, and commercialization rights to histone deacetylase (HDAC) inhibitors, including MethylGene's Phase I MGCD0103 for solid tumors and blood cancers as well as the company's pipeline of second-generation HDAC inhibitors for cancer indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pharmion licenses cancer candidate from MethylGene
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice